Mostrar el registro sencillo del ítem
dc.contributor.author | Albaladejo-García, Virginia | |
dc.contributor.author | Morán, Laura | |
dc.contributor.author | Santos-Coquillat, Ana | |
dc.contributor.author | González, María I | |
dc.contributor.author | Ye, Hui | |
dc.contributor.author | Vázquez Ogando, Elena | |
dc.contributor.author | Vaquero, Javier | |
dc.contributor.author | Cubero, Francisco Javier | |
dc.contributor.author | Desco, Manuel | |
dc.contributor.author | Salinas, Beatriz | |
dc.date.accessioned | 2024-07-04T09:41:35Z | |
dc.date.available | 2024-07-04T09:41:35Z | |
dc.date.issued | 2024-04 | |
dc.identifier.citation | Biomed Pharmacother. 2024 Apr:173:116381. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20040 | |
dc.description.abstract | Curcumin is a natural molecule widely tested in preclinical and clinical studies due to its antioxidant and anti-inflammatory activity. Nevertheless, its high hydrophobicity and low bioavailability limit in vivo applications. To overcome curcumin´s drawbacks, small extracellular vesicles (sEVs) have emerged as potential drug delivery systems due to their non-immunogenicity, nanometric size and amphiphilic composition. This work presents curcumin cargo into milk sEV structure and further in vitro and in vivo evaluation as a therapeutic nanoplatform. The encapsulation of curcumin into sEV was performed by two methodologies under physiological conditions: a passive incorporation and active cargo employing saponin. Loaded sEVs (sEVCurPas and sEVCurAc) were fully characterized by physicochemical techniques, confirming that neither methodology affects the morphology or size of the nanoparticles (sEV: 113.3±5.1 nm, sEVCurPas: 127.0±4.5 nm and sEVCurAc: 98.5±3.6 nm). Through the active approach with saponin (sEVCurAc), a three-fold higher cargo was obtained (433.5 µg/mL) in comparison with the passive approach (129.1 µg/mL). These sEVCurAc were further evaluated in vitro by metabolic activity assay (MTT), confocal microscopy, and flow cytometry, showing a higher cytotoxic effect in the tumoral cells RAW264.7 and HepG2 than in primary hepatocytes, specially at high doses of sEVCurAc (4%, 15% and 30% of viability). In vivo evaluation in an experimental model of liver fibrosis confirmed sEVCurAc therapeutic effects, leading to a significant decrease of serum markers of liver damage (ALT) (557 U/L to 338 U/L with sEVCurAc therapy) and a tendency towards decreased liver fibrogenesis and extracellular matrix (ECM) deposition. | es_ES |
dc.description.sponsorship | This work was partially supported by Comunidad de Madrid (S2022/ BMD-7403 RENIM-CM and EXOHEP2-CM (S2022/BMD-7409) and Ministerio de Ciencia, Innovacion ´ y Universidades, Instituto de Salud Carlos III (grant PI20/01632 and MICINN PID2020-117941RB-I00), cofinanced by European Regional Development Fund (ERDF) (“A way of making Europe”). This work has been supported by European Union Horizon 2020 PRISMAP project and HORIZON-HLTH-2022-STAYHLTH02 under agreement No 101095679. V. Albaladejo-García is grateful for financial support to Consejería de Educacion ´ e Investigacion, ´ cofinanced by European Social Fund (ESF) grant PEJD-2018-PRE/BMD9405. A. Santos-Coquillat grateful for financial support to Consejería de Educacion ´ e Investigacion, ´ co-financed by European Social Fund (ESF) grant PEJD-2018-POST/BMD-9592 and Sara Borrell Fellowship from Ministerio de Ciencia e Innovacion, ´ Instituto de Salud Carlos III grant CD19/00136. Funding for APC: Universidad Carlos III de Madrid (Agreement CRUE-Madrono ˜ 2024). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.mesh | Curcumin | es_ES |
dc.subject.mesh | Extracellular Vesicles | es_ES |
dc.subject.mesh | Saponins | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Milk | es_ES |
dc.subject.mesh | Liver Cirrhosis | es_ES |
dc.title | Curcumin encapsulated in milk small extracellular vesicles as a nanotherapeutic alternative in experimental chronic liver disease. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 38452655 | es_ES |
dc.format.volume | 173 | es_ES |
dc.format.page | 116381 | es_ES |
dc.identifier.doi | 10.1016/j.biopha.2024.116381 | es_ES |
dc.contributor.funder | Comunidad de Madrid (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1950-6007 | es_ES |
dc.relation.publisherversion | 10.1016/j.biopha.2024.116381 | es_ES |
dc.identifier.journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | es_ES |
dc.repisalud.orgCNIC | CNIC::Unidades técnicas::Imagen Avanzada | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/HORIZON-HLTH-2022-STAYHLTH02/101095679 | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/S2022/BMD-7403 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/S2022/BMD-7409 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI20/01632 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/MICINN PID2020-117941RB-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PEJD-2018-POST/BMD-9592 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CD19/00136 | es_ES |